When was Affini-T Therapeutics founded?

Affini-T Therapeutics was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Affini-T Therapeutics located?

Affini-T Therapeutics is headquartered in Watertown, United States.

How many employees does Affini-T Therapeutics have?

As of Sep 30, 2026, the latest employee count at Affini-T Therapeutics is 8.

Is Affini-T Therapeutics a funded company?

Affini-T Therapeutics is a funded company, having raised a total of $193M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2020.

When was the latest funding round of Affini-T Therapeutics?

Affini-T Therapeutics' latest funding was a $***** Series D round on Jul 31, 2024, with participation from 0 investor.

Where does Affini-T Therapeutics rank among its competitors?

Affini-T Therapeutics ranks 949th amongst 3475 active competitors, of which 1158 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Affini-T Therapeutics?

Affini-T Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Affini-T Therapeutics - 2026 Company Profile, Funding & Competitors

Affini-T Therapeutics is a series D company based in Watertown (United States), founded in 2020. It operates as a Developer of T-cell therapies against oncogenic driver mutations. Affini-T Therapeutics has raised $193M in funding from Bayer and Vida Ventures. The company has 3475 active competitors, including 1158 funded and 809 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of T-cell therapies against oncogenic driver mutations. The company has a TCR discovery platform that leverages synthetic biology and gene editing technologies to develop therapies for solid tumor cancers. The company has developed therapies targeting oncogenic driver mutations like KRAS and p53.

Website: affinittx.com
Social
Email ID: *****@affinittx.com

Key Metrics

Founded Year

2020

Location

Watertown, United States

Stage

Series D

Total Funding

$193M in 5 rounds

Latest Funding Round

Series D, Jul 31, 2024, $*****

Investors

Bayer & 9 more

Ranked

949^th among 3475 active competitors

Employee Count

8 as on Sep 30, 2026

Similar Companies

BeiGene & 829 more

View Affini-T Therapeutics' full profile

Affini-T Therapeutics has raised a total funding of $193M over 5 rounds. Its first funding round was on Apr 01, 2020. Affini-T Therapeutics has 10 institutional investors.

Here is the list of recent funding rounds of Affini-T Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 31, 2024	1967506	Series D	8205640	7929476	9297882	5868560
Mar 22, 2022	7889324	Series D	7242912	9351724	2388005	Fred Hutch & 6 more
Jul 01, 2020	9226505	Grant (prize money)	1609609	3207286	1110799	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Affini-T Therapeutics's funding rounds and investors

Affini-T Therapeutics' employee count trend

Affini-T Therapeutics has 8 employees as of Sep 26. Here is Affini-T Therapeutics's employee count trend over the years:

Employee count trend for Affini-T Therapeutics

Uncover Affini-T Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Affini-T Therapeutics include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Affini-T Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
5th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
6th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
7th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
8th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	71/100
949th	Affini-T Therapeutics 2020, Watertown (United States), Series D	Developer of T-cell therapies against oncogenic driver mutations	$193M	Agent Capital, Bayer & 8 others	41/100